Metastatic Castration Resistant Prostate Cancer (mCRPC): Background, Genomics and Treatment

Sep 22, 2021 12:00pm -
Sep 22, 2021 01:00pm

Event Description

(Two-part series)
Description: Each year, there are approximately 14,500 men diagnosed and managed with prostate cancer within the VA system. Up to 40% of men with prostate cancer eventually develop metastatic disease and progression to castration resistance is very common.

This webinar will cover the pathways identified with genomic alterations and how this has led to the approval of PARP inhibitors for treatment of mCRPC.  

DateWednesday September 22, 2021
Time: 12:00 PM ET
Virtual Platform: GoToWebinar
Presenter: Julia Matejec, PharmD MSL
Target Audience: Primary Care, Urologists, Oncologists, Nurses, Pharmacists and other Healthcare professional who care for patients with mCRPC

This webinar is sponsored by:

 astrazeneca-logo | Vyopta

Event Type:Webinar
Early registration ends on Aug 26, 2021.
Regular registration starts on Aug 27, 2021 and ends on Sep 21, 2021.
Late registration starts on Sep 22, 2021.